Characteristics of trials included in the analysis
| Author, year and reference | Patients’ number | Type of DPP-4 inhibitors | Follow-up weeks | Comparator drug | Add-on to | Baseline HbA1c % (mmol/mol) | ΔHbA1c (%) T1: 24–52 weeks | ΔHbA1c (%) T2: 76–104 weeks | Difference (%) T2-T1 95% CI |
|---|---|---|---|---|---|---|---|---|---|
| Foley, 200913 | 409 | Vilda | 104 | Gliclazide | Naive | 8.5 (69) | −0.9 | −0.5 | 0.4 (0.20 to 0.58) |
| Matthews, 201014 | 1051 | Vilda | 104 | Glimepiride | Metformin | 7.3 (56) | −0.25 | −0.1 | 0.15 (0.11 to 0.19) |
| Seck, 201015 | 248 | Sita | 104 | Glipzide | Metformin | 7.3 (56) | −0.8 | −0.54 | 0.26 (0.17 to 0.35) |
| Gallwitz, 201216 | 764 | Lina | 104 | Glimepiride | Metformin | 7.7 (61) | −0.38 | −0.16 | 0.22 (0.16 to 0.28) |
| Scirice, 201317 | 8280 | Saxa | 108 | Placebo | Variable | 8.0 (64) | −0.4 | −0.3 | 0.10 (0.08 to 0.26) |
| White, 201318 | 2701 | Alo | 76 | Placebo | Multiple | 8.0 (64) | −0.5 | −0.33 | 0.17 (0.08 to 0.26) |
| Goke, 200819 | 305 | Vilda | 104 | Metformin | Naive | 8.4 (68) | −1.0 | −1.0 | 0 (−0.17 to 0.17) |
| Rosenstock, 200920 | 354 | Vilda | 104 | Rosiglitazone | Metformin | 8.6 (70) | −1.1 | −0.82 | 0.28 (0.09 to 0.47) |
| Williams-Herman, 201021 | 52 | Sita | 104 | Metformin | None | 8.5 (69) | −1.53 | −1.2 | 0.33 (−0.06 to 0.72) |
| Chacra, 201122 | 56 | Saxa | 76 | Glyburide | Glyburide | 8.5 (69) | −0.64 | 0.03 | 0.67 (0.50 to 0.84) |
| Hollander, 201123 | 186 | Saxa | 76 | Placebo | Thiazo | 8.4 68) | −0.94 | −1.09 | −0.15 (−0.31 to 0.01) |
| Goke, 201324 | 423 | Saxa | 104 | Glipizide | Metformin | 7.65 (60) | −0.74 | −0.41 | 0.33 (0.26 to 0.40) |
Six trials (19–24) are extension studies; Δ, difference from baseline.
alo, alogliptin; lina, linagliptin; sita, sitagliptin; saxa, saxagliptin; thiazo, thiazolidinedione; Vilda, vildagliptin.